miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells
Articles > Article · 2013
Authors: B. Firatligil, Çığır BİRAY AVCI, Y. Baran
JOURNAL OF BUON, Journal Indexed in SCI Expanded, International, 2013, vol 18, pp 437-441
Summary
Purpose: In this study we examined the expression levels of miR-17 which possesses oncogenic activities through downregulation of CDKN1A, p21 and E2F1 tumor suppressor genes, in imatinib sensitive and resistant chronic myeloid leukemia (CML) cells. On the other hand, we also determined the expression levels of miR-17 in response to tyrosine kinase inhibitors imatinib, nilotinib and dasatinib used for the treatment of CML.